Prolight currently have six families of patent applications relating to the Psyros™ single-molecule-counting technology. The first three are currently in the national / regional phases in a range of territories worldwide. Families four and five are in the PCT phase and will enter the national / regional phases later this year. The sixth is a priority application in the UK.
The first 2 patents were granted in Europe in Q2 2025 and are currently being validated in the following 17 European jurisdictions: France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Belgium, Ireland, the Netherlands, Portugal, Sweden, Switzerland, Turkey, Denmark, Finland and Norway. This covers a population base of 540 million people.
Patent EP3987287 protects the core technology and will remain in force until 2040.
Patent EP4264266 is an enhancement to the core technology and will remain in force until 2041.
A divisional application of EP3987287 has also been filed to seek greater scope for the core technology (published as EP4549943).
For MicroFlex, the patent portfolio consists of six registered patents (three in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.
One of the patent applications pertains to how the sampling tube can be directly integrated into the test card. This enables a very simple workflow for all types of clinical environments. No specially trained personnel are needed to pipette and centrifuge the blood sample. MicroFlex thus creates the conditions to offer a fully automated platform for immunodiagnostics.
The most recently approved patent in the United States (May 2025) provides protection for the unique technical composition of the MicroFlex analytical device and reaction chamber. The patent is a testament to the technological height of MicroFlex.
The approved patent from October 2024 concerns a European patent based on a groundbreaking solution for separating plasma from whole blood in a liquid-based consumable. The separation produces high-quality plasma, requires minimal physical space, and is performed in a short amount of time, unlocking new potential business opportunities by integrating the technology into other liquid-based disposable systems.
